166 related articles for article (PubMed ID: 21848499)
1. Monitoring of mycophenolic acid and kidney function during combined immunosuppressive therapy.
Oláh AV; Asztalos L; Ivády G; Varga E; Kovács AM; Kappelmayer J; Varga J
Clin Chem Lab Med; 2011 Nov; 49(11):1849-53. PubMed ID: 21848499
[TBL] [Abstract][Full Text] [Related]
2. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation.
Stracke S; Shipkova M; Mayer J; Keller F; Zarghom A; Yang L; Henne-Bruns D; Wieland E
Clin Transplant; 2012; 26(1):57-66. PubMed ID: 21299636
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients.
Md Dom ZI; Coller JK; Carroll RP; Tuke J; McWhinney BC; Somogyi AA; Sallustio BC
Br J Clin Pharmacol; 2018 Oct; 84(10):2433-2442. PubMed ID: 29974488
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients.
Pons B; Delavenne X; Mehdi M; Maillard N; Sauron C; Berthoux F; Alamartine E; Basset T; Mariat C
Clin Nephrol; 2012 Jun; 77(6):425-31. PubMed ID: 22595383
[TBL] [Abstract][Full Text] [Related]
6. [Immunosuppressive drug monitoring of cyclosporine, tacrolimus, and mycophenolate mofetil in renal transplantation].
Uchida K
Nihon Jinzo Gakkai Shi; 2005; 47(4):423-9. PubMed ID: 15971884
[No Abstract] [Full Text] [Related]
7. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
8. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M
Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
[TBL] [Abstract][Full Text] [Related]
9. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
10. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
[TBL] [Abstract][Full Text] [Related]
11. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
12. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment.
Büchler M; Lebranchu Y; Bénéton M; Le Meur Y; Heng AE; Westeel PF; le Guellec C; Libert F; Hary L; Marquet P; Paintaud G
Clin Pharmacol Ther; 2005 Jul; 78(1):34-42. PubMed ID: 16003290
[TBL] [Abstract][Full Text] [Related]
13. Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Junghanss C; Rathsack S; Wacke R; Weirich V; Vogel H; Drewelow B; Mueller S; Altmann S; Freund M; Lange S
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1061-8. PubMed ID: 22182476
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.
Rostaing L; Christiaans MH; Kovarik JM; Pascual J
Ann Transplant; 2014 Jul; 19():337-45. PubMed ID: 25017487
[TBL] [Abstract][Full Text] [Related]
15. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
16. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
Tönshoff B; David-Neto E; Ettenger R; Filler G; van Gelder T; Goebel J; Kuypers DR; Tsai E; Vinks AA; Weber LT; Zimmerhackl LB
Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
[TBL] [Abstract][Full Text] [Related]
17. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation.
Cattaneo D; Merlini S; Zenoni S; Baldelli S; Gotti E; Remuzzi G; Perico N
Am J Transplant; 2005 Dec; 5(12):2937-44. PubMed ID: 16303008
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients.
Lamba M; Tafti B; Melcher M; Chan G; Krishnaswami S; Busque S
Ther Drug Monit; 2010 Dec; 32(6):778-81. PubMed ID: 20926996
[TBL] [Abstract][Full Text] [Related]
19. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.
Patel CG; Harmon M; Gohh RY; Akhlaghi F
Ther Drug Monit; 2007 Feb; 29(1):87-95. PubMed ID: 17304155
[TBL] [Abstract][Full Text] [Related]
20. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
